Rifaximin in the treatment of irritable bowel syndrome: Is there a high risk for development of antimicrobial resistance?

Journal of Clinical Gastroenterology

Volumn 47, Issue 3, 2013, Pages 205-211

  Farrell, David J ^a  

^a JMI LABORATORIES   (United States)

Author keywords

antibiotic resistance; irritable bowel syndrome; rifaximin

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; ISONIAZID; MACROLIDE; METICILLIN; METRONIDAZOLE; PENICILLIN DERIVATIVE; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAXIMIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG ABSORPTION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENTERITIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IRRITABLE COLON; MENINGITIS; MENINGOCOCCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL COMMUNITY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; TRAVELLER DIARRHEA; TUBERCULOSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; RIFAMYCINS; TIME FACTORS;

EID: 84873989133     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31827559a3     Document Type: Review

References (97)

1. Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med. 2011;364:81-82.
2. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
3. Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802-808.
4. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19:141-150, vii.
5. Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-1301.
6. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo- controlled study. Am J Gastroenterol. 2003;98:412-419.
7. Nayak AK, Karnad DR, Abraham P, et al. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called "chronic amebiasis". Indian J Gastroenterol. 1997;16:137-139.
8. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci. 2005;50:758-766.
9. Moayyedi P, Duffett S, Mason S, et al. The influence of antibiotics on irritable bowel syndrome: a randomised controlled trial. Gastroenterology. 2002;122:A-465, Poster #T1487.
10. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51:36-66.
11. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs. 2005;65: 1697-1713.
12. Calvori C, Frontali L, Leoni L, et al. Effect of rifamycin on protein synthesis. Nature. 1965;207:417-418.
13. Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14:290-295.
14. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14: 551-556.
15. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781-786.
16. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563.
17. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci. 2011;56:2067-2072.
18. FDA-issued complete response letter indicating non-approval of rifaximin sNDA for IBS. Available at: http://www.salix.com/news-media/news/index/salix- receives-anticipated-fda-complete-response-letter-on-xifaxan%C2%AE-550-mg- tabletsnon-c-ibs-supplemental-new-drug-application.aspx. Accessed December 27, 2011.
19. United States Food and Drug Administration. Minutes from the Gastrointestinal Drugs Advisory Committee Meeting 16 November 2011 on rifaximin retreatment study. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ GastrointestinalDrugsAdvisoryCommit tee/UCM279646.pdf. Accessed December 27, 2011.
20. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5:S402-S406.
21. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983;5:S407-S411.
22. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205-2206.
23. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinalselective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26:17-25.
24. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951.
25. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
26. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506.
27. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-1286.
28. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidencebased position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104:S1-35.
29. Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169-174.
30. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103:2031-2035.
31. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th ed. Washington, DC: ASM Press; 2005.
32. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
33. Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163: 1279-1285.
34. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467-484.
35. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52:2813-2817.
36. Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000;46: 253-266.
37. Malvisi Stracciari J, Venturini AP, Anfossi P, et al. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia. 1987;6:82-84.
38. Soro O, Pesce A, Raggi M, et al. Selection of rifampin resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect. 1997;3:147-151.
39. Ruiz J, Mensa L, Pons MJ, et al. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother. 2008;61:1016-1019.
40. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res. 1986;12:979-981.
41. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009-1011.
42. Vitali B, Turroni S, Serina S, et al. Molecular and phenotypic traits of in vitro-selected mutants of Bifidobacterium resistant to rifaximin. Int J Antimicrob Agents. 2008;31:555-560.
43. Senol G, Erbaycu A, Ozsoz A. Incidence of cross-resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother. 2005;17:380-384.
44. Valentin T, Leitner E, Rohn A, et al. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34-38.
45. World Health Organization. Global Tuberculosis Control. WHO Report. Geneva, Switzerland: World Health Organization; 2011.
46. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810-814.
47. World Health Organization. Multidrug and Extensively Drugresistant TB (M/XDR-TB). WHO 2010 Global Report on Surveillance and Response. Geneva, Switzerland: World Health Organization; 2010.
48. Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ. 2006;333:559-560.
49. Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis: a model to increase access to drugs and treatment. Science. 2001;293:1049-1051.
50. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474-481.
51. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4:e6914.
52. World Health Organization. Emergence of XDR-TB: WHO concern over extensive drug resistant TB strains that are virtually untreatable. Available at: http://www.who.int/mediacentre/news/notes/2006/np23/en/index.html. Accessed on September 28, 2011.
53. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N Engl J Med. 2008;359: 657-659.
54. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423-430.
55. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328:527-532.
56. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 1981;81:5-9.
57. Nakamura S, Mikawa M, Nakashio S, et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol. 1981;25:345-351.
58. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
59. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18: 247-263.
60. Olson MM, Shanholtzer CJ, Lee JT Jr, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15:371-381.
61. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
62. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219-1227.
63. McFarland LV, Beneda HW, Clarridge JE, et al. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control. 2007;35:237-253.
64. Cohen S, Gerding D, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
65. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-1590.
66. Huang H, Weintraub A, Fang H, et al. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents. 2009;34:516-522.
67. Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol. 2010;3: 221-225.
68. Farrell DJ, Putnam SD, Biedenbach DJ, et al. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with travelers' diarrhea and Clostridium difficile. Antimicrob Agents Chemother. 2011;55:992-996.
69. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009;48:425-429.
70. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1432-1442.
71. David MZ, Daum RS. Community-associated methicillinresistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616-687.
72. Barber M. Methicillin-resistant staphylococci. J Clin Pathol. 1961;14:385-393.
73. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-1771.
74. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42: 1303-1304.
75. Rehm SJ, Tice A. Staphylococcus aureus: methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycinresistant S. aureus. Clin Infect Dis. 2010;51:S176-S182.
76. Cui L, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother. 2000;44:2276-2285.
77. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-1347.
78. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355: 653-665.
79. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422-1429.
80. Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother. 1997;39:235-240.
81. Cui L, Isii T, Fukuda M, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54: 5222-5233.
82. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis. 1985;7:504-510.
83. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
84. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327-1348.
85. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev. 1989;2:S118-S124.
86. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS. 1998;106:505-525.
87. Global alert and response. Meningococcal disease. Available at: http://www.who.int/csr/disease/meningococcal/en/index.html. Accessed September 30, 2011.
88. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-191.
89. Fraser A, Gafter-Gvili A, Paul M, et al. Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials. Eur J Clin Microbiol Infect Dis. 2005;24:172-181.
90. Rainbow J, Cebelinski E, Bartkus J, et al. Rifampin-resistant meningococcal disease. Emerg Infect Dis. 2005;11:977-979.
91. Jackson LA, Alexander ER, DeBolt CA, et al. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. Pediatr Infect Dis J. 1996;15:992-998.
92. Weidmer CE, Dunkel TB, Pettyjohn FS, et al. Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains. J Infect Dis. 1971;124:172-178.
93. Almog R, Block C, Gdalevich M, et al. First recorded outbreaks of meningococcal disease in the Israel Defence Force: three clusters due to serogroup C and the emergence of resistance to rifampicin. Infection. 1994;22:69-71.
94. Gorla MC, de Paiva MV, Salgueiro VC, et al. Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008. Enferm Infecc Microbiol Clin. 2011;29:85-89.
95. Carter PE, Abadi FJ, Yakubu DE, et al. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob Agents Chemother. 1994;38:1256-1261.
96. Stefanelli P, Fazio C, La Rosa G, et al. Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. J Antimicrob Chemother. 2001;47:219-222.
97. Skoczynska A, Ruckly C, Hong E, et al. Molecular characterization of resistance to rifampicin in clinical isolates of Neisseria meningitidis. Clin Microbiol Infect. 2009;15:1178-1181.